Key facts
- This page summarizes Eric E. Poma's Form 4 filing for Calidi Biotherapeutics, Inc. (CLDI).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 25 Apr 2025, 06:05.
Eric E. Poma - 22 Apr 2025 Form 4 Insider Report for Calidi Biotherapeutics, Inc. (CLDI)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- CLDI
- Reported as of
- 22 Apr 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Apr 2025, 06:05:05 UTC
- Prior SEC filing
- 25 Jan 2024
- Next SEC filing
- 25 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrew Jackson, Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric E. Poma filed Form 4 for Calidi Biotherapeutics, Inc. (CLDI) on 25 Apr 2025.
Change
- Previous filing in this sequence was filed on 25 Jan 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLDI
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +726,412
- Change %
- Price
- Shares after
- 726,412
- Date
- 22 Apr 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 726,412
- Exercise price
- $0.4690
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On April 22, 2025 (the "Grant Date"), the compensation committee and board of directors of Calidi Biotherapeutics, Inc. ("Issuer") approved an inducement grant to the Reporting Person of 726,412 stock options (the "Options"), pursuant to the exception under Section 711 NYSE American, at a per share exercise price of $0.4690, which is equal to the closing price of the Issuer's common stock on the Grant Date.
Footnote F2
25% of the options will vest upon the one (1) year anniversary of 04/22/2025, and the remaining 75% of the options will vest in 1/36th installments on the last day of each monthly period subject to the Reporting Person's continued service to the Issuer.
SEC remarks
Exhibit 24 - Power of Attorney